Non-GAAP EPS guidance for 2025 was increased to a range of $6.70 to $7.00, up $0.15 at the midpoint from initial guidance. Total revenue reached $11.2 billion, with growth portfolio revenues ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

Thanks to 2022’s No Surprises Act, if you have a medical emergency and call 911, you no longer have to worry about being ...

Good day, and welcome to the Bristol Myers Squibb First Quarter 2025 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there ...

The NHS carries out around five million CT scans a year for reasons such as assessing internal injuries after an accident and ...

While it has been widely found that farmworkers bear the brunt of agricultural pesticide exposures in fields and outbuildings ...

This patient group represents approximately 30% of the broader colorectal cancer (CRC) population. The company's strong financial position, with a remarkable 96.25% gross profit margin and 17.31% ...

Patients with HPV16-positive head and neck cancer represents a large fast growing ... of Versamune MUC1 and PDS01ADC to treat metastatic colorectal cancer. This is a significant development ...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small ...

The response, he said, was that Britain’s position was that the referendum be held a year after the lifting of restrictions ...

Join us for a quick overview of BioNTech SE, a Biotechnology company whose shares moved 0.3% today. Here are some facts about ...